[{"id":"65064bc2-1932-4c3f-9286-d20035f5b081","acronym":"","url":"https://clinicaltrials.gov/study/NCT05734560","created_at":"2023-02-21T16:01:36.908Z","updated_at":"2024-07-02T16:35:36.132Z","phase":"Phase 1/2","brief_title":"D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients","source_id_and_acronym":"NCT05734560","lead_sponsor":"Darell Bigner","biomarkers":" MGMT","pipe":" | ","alterations":" RAS wild-type • IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 2141-V11 • D2C7-IT"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2023-09-21"}]